NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026
- NHS England
Procurement identifier (OCID): ocds-h6vhtk-051c98
Description
NHS Branded Framework Agreement - Lot 1 - Tranche A for the North of England and Midlands & East.
Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority's discretion for a further 24 months.
Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
Notices
UK7: Contract details notice
- Notice identifier
- 2026/S 000-068603
- Published
- 21 July 2026, 11:16am
UK6: Contract award notice
- Notice identifier
- 2026/S 000-064847
- Published
- 9 July 2026, 3:45pm
9 July 2026, 3:45pm (latest version)
- 23 June 2026, 12:33pm
UK4: Tender notice
- Notice identifier
- 2026/S 000-023990
- Published
- 17 March 2026, 12:14pm
UK2: Preliminary market engagement notice
- Notice identifier
- 2026/S 000-023102
- Published
- 13 March 2026, 3:08pm
13 March 2026, 3:08pm (latest version)
- 13 January 2026, 9:57am
UK1: Pipeline notice
- Notice identifier
- 2025/S 000-029473
- Published
- 3 June 2025, 12:41pm
3 June 2025, 12:41pm (latest version)
- 22 May 2025, 9:34am